“ambr15 for cell culture process optimization” Webinar 3P Biopharmaceuticals and Sartorius Stedim Biotech

Did you miss our webinar about our experience using ambr® 15 with CHO-S cell line for the production of monoclonal antibodies?

High-throughput media and feed screening for cell culture process optimization with multi-parallel micro bioreactors

Watch it now!

In the development and delivery of high quality therapeutic proteins, high throughput process development tools can really accelerate early process understanding.

ambr® 15 cell culture system offers an alternative approach to shake flask or conventional benchtop bioreactors in an automated, multi-parallel, high throughput format. The system can be implemented within the Upstream process workflow to generate early process development data at the small scale with very low demands on operator time, set-up and turn around due to automation and single-use components, and improve global costs of development due to the minimum scale the equipment is designed to operate.

In this webinar Dr Marta Ruiz Guillén, USP development expert at 3P Biopharmaceuticals, and Javier Lobo, Field Marketing Manager for Sartorius Stedim Biotech in Latin America, Spain & Portugal; discuss the methods and results from performing media and feed screening evaluations in ambr® 15 with CHO-S cell line producing monoclonal antibodies and demonstrate the effectiveness of ambr 15 for rapid and robust cell culture process development.

Watch it now and learn more about the experiments performed:

  • Screening of different media
  • Evaluation of different feeds
  • Effect of supplements
  • Optimization of feed strategy

Our dedicated team of specialists will be happy to discuss any of your Biopharmaceutical Manufacturing needs. Contact us on +34 948 346 480 or email withinus@3pbio.com

Related Content

BrainEver and 3P Biopharmaceuticals collaborate on development of recombinant human homeoprotein Engrailed-1

Published: 15th November 2022
3P Bio will focus on the transfer of the production process as well as the cGMP manufacturing of the drug substance to be used in Phase I and II clinical trials. The novel drug could cure neurodegenerative diseases such as Amyotrophic Lateral Sclerosis.
Read more

3P Biopharmaceuticals awards the prize for the best Master’s Thesis (TFM)

Published: 3rd October 2022
At the closing of the fifth edition of the Master in Galenic Design and Manufacturing in the Pharmaceutical Industry of the University of Navarra.
Read more

3P Biopharmaceuticals among the 100 best companies to work for in Spain

Published: 27th September 2022
The prestigious ranking is based on an exhaustive questionnaire that Actualidad Económica prepares and publishes every year, and which seeks to evaluate and reward those companies whose human resources management makes them benchmarks.
Read more

Get in touch

Let’s discuss your biologics journey.

Discover more about our people, our passion, and how we can work together to improve lives.